Abstract
Our study suggests that UBE2CP3 can enhance the interaction between HCC tumor cells and HUVECs and promote HCC tumorigenicity by facilitating angiogenesis.
Introduction
Hepatocellular carcinoma (HCC) is notorious for being a "hypervascular" tumor—it is exceptionally good at stimulating the growth of new blood vessels (angiogenesis) to sustain its rapid growth and facilitate metastasis. While we know that Vascular Endothelial Growth Factor A (VEGFA) is a primary driver of this process, the upstream "switches" that tell cancer cells to pump out VEGFA are not fully understood. This paper investigates UBE2CP3, a pseudogene-derived lncRNA, to see if it controls the "angiogenic switch" that powers liver cancer progression.
Methods
The authors employed a multi-disciplinary approach to bridge the gap between clinical observation and molecular mechanism:
- Clinical Correlation: They analyzed 94 HCC patient samples using In Situ Hybridization (ISH) and qRT-PCR to measure UBE2CP3 levels, correlating them with endothelial vessel (EV) density (measured by CD31 staining) and patient survival.
- Cell Engineering: They created stable HCC cell lines (HepG2 and SMMC-7721) that either overexpressed or "knocked down" UBE2CP3.
- The Co-culture Model: To study how cancer cells talk to blood vessels, they used a Transwell co-culture system allowing secreted factors to pass between HCC cells and Human Umbilical Vein Endothelial Cells (HUVECs).
- Functional and In Vivo Assays: They measured HUVEC proliferation, migration, and tube formation, and validated findings using Chick Embryo Chorioallantoic Membrane (CAM) and nude mouse xenograft models.
Key Insights and Results
High expression of UBE2CP3 in HCC tissues strongly correlates with higher vessel density and significantly shorter overall survival for patients. Mechanistically, UBE2CP3 changes the tumor microenvironment by turning cancer cells into VEGFA factories via the UBE2CP3 → ERK1/2 activation → HIF-1α/p70S6K stabilization → VEGFA secretion pathway.
Key findings include:
- Clinical Impact: Patients with high UBE2CP3 expression and high vessel density had the worst prognosis (P=0.0003).
- Functional Boost: HUVECs exposed to "high-UBE2CP3" cancer cell secretions showed marked increases in migration and tube formation.
- Reversibility: The pro-angiogenic effects could be blocked by neutralizing VEGFA or inhibiting the ERK pathway.
Limitations and Future Work
While the study defines the signaling cascade, the initial physical interaction between the lncRNA UBE2CP3 and the ERK protein complex remains to be fully elucidated. Future research will focus on identifying direct protein binding partners to further refine potential therapeutic targets for HCC.
Summary updated